Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Molecular Psychiatry
|
June 5, 2024
iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease
Cristina Zivko, Ram Sagar, Ariadni Xydia, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
March 17, 2011
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
D P Devanand, Jacobo Mintzer, Susan Schultz, et al.
Depression and Anxiety
|
July 27, 2004
Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study
Ziad Nahas, Xingbao Li, F Andrew Kozel, et al.
Neurology
|
September 13, 2015
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
R Scott Turner, Ronald G Thomas, Suzanne Craft, et al.
The New England Journal of Medicine
|
October 19, 2012
Relapse risk after discontinuation of risperidone in Alzheimer's disease
D P Devanand, Jacobo Mintzer, Susan K Schultz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
March 12, 2025
Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care
Soo Borson, Rhoda Au, Anna H Chodos, et al.
Trials
|
January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
Roberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
The American Journal of Psychiatry
|
November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations
Anjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Alzheimer'S Research & Therapy
|
May 24, 2026
Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial
Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, et al.
International Psychogeriatrics
|
March 6, 2023
Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm
Jeffrey Cummings, Mary Sano, Stefanie Auer, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Molecular Psychiatry
|
June 5, 2024
iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease
Cristina Zivko, Ram Sagar, Ariadni Xydia, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
March 17, 2011
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
D P Devanand, Jacobo Mintzer, Susan Schultz, et al.
Depression and Anxiety
|
July 27, 2004
Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study
Ziad Nahas, Xingbao Li, F Andrew Kozel, et al.
Neurology
|
September 13, 2015
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
R Scott Turner, Ronald G Thomas, Suzanne Craft, et al.
The New England Journal of Medicine
|
October 19, 2012
Relapse risk after discontinuation of risperidone in Alzheimer's disease
D P Devanand, Jacobo Mintzer, Susan K Schultz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
March 12, 2025
Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care
Soo Borson, Rhoda Au, Anna H Chodos, et al.
Trials
|
January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
Roberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
The American Journal of Psychiatry
|
November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations
Anjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Alzheimer'S Research & Therapy
|
May 24, 2026
Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial
Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, et al.
International Psychogeriatrics
|
March 6, 2023
Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm
Jeffrey Cummings, Mary Sano, Stefanie Auer, et al.
Page
of 7